✦ LIBER ✦

352 TIME TO DISEASE PROGRESSION IS NOT AN APPROPRIATE ENDPOINT IN STUDIES OF IMMEDIATE VERSUS DEFERRED/SALVAGE ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER

✍ Scribed by Studer, Urs; Whelan, Peter; Wimpissinger, Florian; Casselman, Jacques; De Reijke, Theo M.; Kn̈onagel, Harmut; Madersbacher, Stefan; Isorna, Santiago; Sundaram, Subramanian K.; Collette, Laurence

Book ID: 122623533
Publisher: Lippincott Williams and Wilkins
Year: 2011
Tongue: English
Weight: 153 KB
Volume: 185
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2011.02.437

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

801 TIME TO PROGRESSION SHOULD NOT BE US

801 TIME TO PROGRESSION SHOULD NOT BE USED TO INFER THE ULTIMATE BENEFIT OF IMMEDIATE VERSUS DEFERRED/SALVAGE ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER

✍ U.E. Studer; P. Whelan; F. Wimpissinger; J. Casselman; Th.M. De Reijke; H. Knöna 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 221 KB

Differences in Time to Disease Progressi

Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12Years of Follow-up

✍ Kibel, A.S. 📂 Article 📅 2014 🏛 Elsevier Science ⚖ 46 KB